Article info

Download PDFPDF

621 Risk of damage progression with belimumab versus oral immunosuppressant use in patients with systemic lupus erythematosus

Authors

Citation

Jorge A, Zhou B, Zhang Y, et al
621 Risk of damage progression with belimumab versus oral immunosuppressant use in patients with systemic lupus erythematosus

Publication history

  • First published May 16, 2024.
Online issue publication 
May 16, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.